Abstract
The COVID-19 pandemic has undergone frequent and rapid changes in its local and global infection rates, driven by governmental measures, or the emergence of new viral variants. The reproduction number Rt indicates the average number of cases generated by an infected person at time t and is a key indicator of the spread of an epidemic. A timely estimation of Rt is a crucial tool to enable governmental organizations to adapt quickly to these changes and assess the consequences of their policies. The EpiEstim method is the most widely accepted method for estimating Rt. But it estimates Rt with a significant temporal delay. Here, we propose a new method, EpiInvert, that shows good agreement with EpiEstim, but that provides estimates of Rt several days in advance. We show that Rt can be estimated by inverting the renewal equation linking Rt with the observed incidence curve of new cases, it. Our signal processing approach to this problem yields both Rt and a restored it corrected for the “weekend effect” by applying a deconvolution + denoising procedure. The implementations of the EpiInvert and EpiEstim methods are fully open-source and can be run in real-time on every country in the world, and every US state through a web interface at www.ipol.im/epiinvert.
Significance Statement Based on a signal processing approach we propose a method to compute the reproduction number Rt, the transmission potential of an epidemic over time. Rt is estimated by minimizing a functional that enforces: (i) the ability to produce an incidence curve it corrected of the weekly periodic bias produced by the “weekend effect”, obtained from Rt through a renewal equation; (ii) the regularity of Rt. A good agreement is found between our Rt estimate and the one provided by the currently accepted method, EpiEstim, except our method predicts Rt several days closer to present. We provide the mathematical arguments for this shift. Both methods, applied every day on each country, can be compared at www.ipol.im/epiinvert.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No Funding statement declared
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No approval necessary; only public and anonymous data were used
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵1 Luis Alvarez. E-mail: lalvarez{at}ulpgc.es
L. Alvarez and J-M. Morel designed and performed research and experiments and wrote the paper. L. Alvarez implemented the method. M. Colom built the online interface and collected and processed data. J.D. Morel rewrote parts and designed the statistical analysis and presentation of the results.
The authors declare no competing interests
Inclusion of simulations to validate the results
↵§ https://raw.githubusercontent.com/nytimes/covid-19-data/master/us-states.csv
Data Availability
We use the COVID-19 registered daily infected from https://ourworldindata.org
